Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?

Pediatr Blood Cancer. 2010 May;54(5):661-2. doi: 10.1002/pbc.22410.
No abstract available

Publication types

  • Comment

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols
  • Camptothecin / administration & dosage
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives*
  • Camptothecin / pharmacokinetics
  • Child
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Irinotecan
  • Maximum Tolerated Dose

Substances

  • Antineoplastic Agents, Phytogenic
  • Irinotecan
  • Camptothecin